Arthritis & Rheumatism, Volume 60,
October 2009 Abstract Supplement

The 2009 ACR/ARHP Annual Scientific Meeting
Philadelphia October 16-21, 2009.


Rheumatoid Arthritis: Insights, Strategies and ExpectationsGlobal Results of the RAISE Patient Needs Survey

McInnes1,  Iain B., Combe2,  B., Burmester3,  Gerd R.

University of Glasgow, Glasgow, United Kingdom
Immuno-Rheumatology, Montpellier, France
Charite University Hospital, Berlin, Germany

Purpose:

Understanding the perceptions of patients who live with rheumatoid arthritis (RA) and their views on its treatment can provide a valuable perspective to the rheumatologist and may help to shape our management strategies. The RAISE survey was designed to reveal the perceptions of RA patients on their disease and therapy.

Method:

A questionnaire was developed with input from 53 rheumatologists from 8 European countries and Canada. Questions included, but were not limited to, the following topics: diagnosis, disease information sources, daily living with RA, quality of life (QoL) and views on current therapy and treatment options. Surveyed patients were either on biologic therapy or biologic naïve but eligible for biologic treatment based on broad criteria of a DAS28 >3.2 or an acute phase response, plus erosive disease and moderate-to-severe active RA.

Results:

A total of 586 patients, approximately 30 biologic naïve and 35 on anti-TNF therapy from each of 9 countries, were interviewed. Mean age at onset of RA symptoms was 41 years. Patients reported that most physician-patient communication centered on symptoms and treatment; less frequently discussed was the impact of RA on QoL. While all patients reported improvement on their current versus previous treatment, biologic users had significantly more 'good' days per month than biologic-naïve patients (71% vs 61%, respectively). The survey revealed a large percentage of patients (22%) reporting high levels of pain. For most patients, biologic therapy improved their symptoms and overall QoL compared with their previous non-biologic therapy. Biologic-experienced patients were significantly more satisfied with their treatment than biologic-naïve patients. Patients (41%) use the internet as a resource for information about RA. Approximately 20% of biologic users require help (emotional and/or physical) in preparing and/or administering subcutaneous injections and have concerns around injection site pain or irritation. Despite being eligible for biologic therapy by a broad definition of criteria, 62% of biologic-naïve patients were not aware of biologic therapies and the majority (88%) were never recommended a biologic treatment. Factors influencing willingness to try a new medication included symptom control, stopping disease progression and improving the overall experience of living with RA. Patients were most interested in a product that worked consistently (76%), was simple to use (69%) and had a less frequent dosing schedule (75%).

Conclusion:

This large patient survey provides key insights into how RA patients live with their disease and how therapy has impacted them. The data reveal that biologic therapy has had significant impact on improving patients' lives. However, all patients reported some level of continuing symptoms and current pain indicating unmet clinical need.

To cite this abstract, please use the following information:
McInnes, Iain B., Combe, B., Burmester, Gerd R.; Rheumatoid Arthritis: Insights, Strategies and ExpectationsGlobal Results of the RAISE Patient Needs Survey [abstract]. Arthritis Rheum 2009;60 Suppl 10 :1595
DOI: 10.1002/art.26669

Abstract Supplement

Meeting Menu

2009 ACR/ARHP